Drug intelligence / Profile preview

Liposic EDO Gel + diquafosol tetrasodium + hyaluronic acid

Development stage
Unknown
Lead developer
Bausch + Lomb
Modality
Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
Administration
Ophthalmic
01

Overview

This is a combination ophthalmic therapy for dry eye disease, consisting of three components: - **Liposic EDO Gel** (a carbomer-based gel): Acts as a tear substitute, providing lubrication and mimicking the natural tear film to relieve symptoms of dry eye such as irritation and burning. It forms a protective layer over the ocular surface, improving moistening and comfort[1][3]. - **Diquafosol tetrasodium**: A small molecule P2Y2 receptor agonist that stimulates fluid secretion from conjunctival epithelial cells and promotes mucin secretion from goblet cells. This enhances both the aqueous and mucin layers of the tear film, improving tear stability and ocular surface health[5][6][9]. - **Hyaluronic acid** (sodium hyaluronate): A naturally occurring glycosaminoglycan with strong water-retaining properties. It hydrates the ocular surface, promotes epithelial healing, reduces inflammation, and increases tear film stability[2][4][6]. The combination is designed to address multiple aspects of dry eye pathophysiology by lubricating (carbomer gel), stimulating endogenous fluid/mucin production (diquafosol), and hydrating/protecting tissue (hyaluronic acid). Clinical studies suggest that combining diquafosol with hyaluronic acid provides superior improvement in subjective symptoms, visual performance after LASIK surgery, Schirmer test values (tear production), corneal staining scores, and overall efficacy compared to monotherapy with either agent alone[6][8]. The product is primarily indicated for mild-to-severe dry eye disease.

02

Targets

MUC (Mucin family)P2RY2 (P2Y Purinoceptor 2)

Beyond the preview

Go deeper on Liposic EDO Gel + diquafosol tetrasodium + hyaluronic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liposic EDO Gel + diquafosol tetrasodium + hyaluronic acid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call